Decitabine/cedazuridine (NCT05960773)

Name: Decitabine/cedazuridine trial for Mesothelioma (NCT05960773)
Uploaded: 2026-10-31T06:28:58.826Z
Duration: 1 min 17 s
Description: Decitabine/cedazuridine trial for Mesothelioma (NCT05960773). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05960773.

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma: a one-minute explainerNCT059607731 min

Decitabine/cedazuridine trial for Mesothelioma (NCT05960773). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people aged 18–120 with inherited BAP1 mutations and biopsy-confirmed early mesothelioma. Standard-treatment need and refusal criteria require individual review.

The idea: use decitabine/cedazuridine to interfere with DNA methylation. Cedazuridine prevents decitabine breakdown; decitabine inhibits DNA methyltransferase. Tablets are taken on three consecutive days per 28-day cycle for six cycles. Stable or improving disease can qualify for six more. Chest or abdominal scopes with biopsies assess disease before and after treatment.

This phase 2 study plans 15 patients. David Schrump leads at NIH in Bethesda, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.